Stereochemistry | ACHIRAL |
Molecular Formula | C16H14N2O3 |
Molecular Weight | 282.294 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3
InChI
InChIKey=BYFMCKSPFYVMOU-UHFFFAOYSA-N
InChI=1S/C16H14N2O3/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12/h1-9H,10-11H2,(H,19,20)
Molecular Formula | C16H14N2O3 |
Molecular Weight | 282.294 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bendazac, (1-benzyl-1H-indazol-3-yl-oxy)-acetic acid, is structurally related to indomethacin. Its lysine salt has been reported to be absorbed better than the parent compound. It is applied topically as bendazac lysine 0.5% (wt/vol) aqueous solution for delaying the progression of cataract. Topical application of bendazac is associated with transient burning sensation. It reduces the secretion of the skin ulcer surface, promotes skin formation and accelerates tissue repair.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Single Dose Eye drops: 2 drops in each eye or half the contents of a single-dose, three times a day
Multi-dose eye drops: 2 drops in each eye, three times a day
oral: single dosage benzadac lysine in tables (500 mg)
Skin ulcers: An appropriate amount of this product is applied to the affected area several times a day. Incidentally, it performs patch therapy 1-2 times daily as needed.
Inflammatory skin disease: An appropriate amount of this product is applied to the affected area several times a day.
Route of Administration:
Other